Background: Patients requiring invasive mechanical ventilation in the intensive care unit (ICU) are at risk for ventilator-associated pneumonia (VAP). Objectives: To summarize the results of published, randomized, clinical trials (RCTs), a meta-analysis was performed to examine the effect of subglottic secretion drainage (SSD) on the prevalence and outcomes of VAP in adult patients undergoing mechanical ventilation. Methods: A comprehensive search based on specific terms was performed as a systematic review and meta-analysis by a computerized database search in the national and international databases including MagIran, SID, Scopus, PubMed, ISI Web of Knowledge, ScienceDirect, Google Scholar, Cochrane Central, and IRCT as well as references from 1990 to 2018 in English and Persian languages. RCTs of SSD were considered as common care of adult patients undergoing mechanical ventilation in the current meta-analysis. Data analysis was carried out through the random and fixed effects model, and the heterogeneity was investigated by I2 and Q-Cochrane index. The data were analyzed using STATA 11. Results: A total of 24 eligible RCTs with 2434 patients were identified. The overall risk ratio for VAP was 14.7 (95% confidence interval (CI): 11.1 -18.4); mortality 3); length of ICU stay 13.4 (95% CI: 7.8 -18.9) and hospital stay 23.2 (95% CI: 12.5 -33.9); ventilation days 14.9 (95% CI: 7.3 -22.6); airway secretion 10.2 (95% CI: 4.9 -15.5); and APACHEII 19.5 (95% CI: 14.6 -24.3). Conclusions: SSD is recommended to prevent VAP, and reduce mortality rate and the ICU LOS, especially in the high-risk patients undergoing mechanical ventilation for a long period of time.
Background
The risk for ventilator-associated pneumonia (VAP) is high in patients requiring invasive mechanical ventilation (MV) (1) . The rate of VAP is 1 -53 cases per 1000 ventilator days in European and North American ICU (intensive care unit) settings (2) . VAP occurs in 9% -35.4% of patients receiving MV (3, 4) . The mortality rate of VAP is estimated 9% -76% (2-4).
Prolonged length of hospital stay (LOS) and ICU stay are attributed to VAP incidence and can cause increased healthcare costs (5-7) and antibiotic consumption (8, 9) .
The microaspiration of pathogenic microorganisms from the upper respiratory tract (trachea and oropharynx) secretions is a primary mechanism of VAP; due to impairment of laryngeal function by the endotracheal tube (ETT), mechanically ventilated patients are at a very high risk for microaspiration (10) .
specially designed ETT and attempting the subglottic secretion drainage (SSD) are considered as VAP prevention strategies to reduce the risk of VAP in patients admitted to ICU (8, 11) ; therefore, use of SSD, conical cuff shape, and continuous control of tracheal cuff pressure are the preventive measures for microaspiration and VAP (12) .
Several published studies declared that SSD was associated with a lower rate of VAP, but the effect of SSD on the incidence of late-onset VAP, duration of MV, and ICU or hospital LOS is unclear. The results of several randomized, controlled trials (RCTs) investigated the effect of SSD on VAP were inconclusive and summarized in some metaanalyses (13) (14) (15) (16) (17) (18) ; however, systematic reviews and metaanalyses reported no significant differences between continuous and intermittent SSD in terms of the treatment outcomes (19) . However, previous meta-analyses reported that SSD decreased the risk of VAP (13) (14) (15) (16) (17) (18) , duration of MV (13) (14) (15) (16) 18) , delayed VAP onset (15, 18) , and ICU LOS (13, 16) . According to the results of some meta-analyses, comparison of the SSD and control groups showed no reduction in ICU or hospital mortality rate (13) (14) (15) (16) 18) , the incidence of lateonset VAP, or ICU or hospital LOS (14, 15, 20) . Although use of SSD may provide important benefits to patients, their families, and healthcare system, evidence show that SSD may not decrease the mortality rate as applying ETT with SSD imposes higher cost to the healthcare providers and may increase the airway resistance because of the narrowed inner lumen (15) .
Therefore and despite the reported benefits of SSD in studies, this procedure is limited in clinical settings (17) and European consensus does not recommend SSD for VAP prevention (15) . Therefore, it is necessary to conduct an umbrella review of systematic reviews and meta-analysis and update the studies to provide more strong evidence.
Objectives
To summarize the results of published RCTs, a metaanalysis was performed to examine the effect of SSD on the prevalence and outcomes of VAP in adult patients undergoing MV.
Methods

Protocol and Registration
In the current umbrella review and meta-analysis, critically ill patients receiving invasive MV or endotracheal intubation were included. No changes were made to the protocol after the start of the study. No registration was also available for the study.
Eligibility Criteria
The inclusion criteria were: patients ≥ 18 years old; receiving MV ≥ 48 hours; receiving SSD irrespective of intermittent or continuous form; patients diagnosed with VAP; studies with experimental design-i e, RCTs, with full text available in English or/and Persian languages. The English and Persian languages were selected due to authors' language capabilities. The exclusion criterion was the duplicate papers.
Information Sources
The electronic databases were searched from January 1990 to March 2018 by two researchers in English and Persian languages.
Search Strategy
The following keywords were used: "ventilatorassociated pneumonia"; "subglottic secretion" or "subglottic drainage" or "subglottic suctioning" or "glottic"; and "randomized" or "randomised"; moreover, the reference list of conference proceedings and review articles were searched manually. For unpublished trials, the investigators searched the clinical trial registers, conference proceedings, and graduate dissertations; in addition, researchers corresponded through email with some authors. The syntax of Scopus, PubMed, and ISI Web of Knowledge were available on Scopus: (TITLE-ABS-KEY ("ventilator-associated pneumonia" OR "subglottic secretion" OR "subglottic drainage" OR "subglottic suctioning" OR "glottis") AND TITLE-ABS-KEY ("randomized" OR "randomized"); PubMed: ("ventilator- "subglottic suctioning" OR "glottis") AND TOPIC: ("randomized" OR "randomised").
Relevant Studies Quality Assessment
Critical appraisal (CA) was performed by applying the evidence-based library (EBL) critical appraisal checklist (21) by two researchers. The EBLCA checklist includes the calculations for the validity of the studies. Population, data collection, study design, and results are the four main categories of the checklist employed. Items are answered by choosing each of the Yes, No, Unclear, or Not Applicable options. According to the CA checklist, if number of yes/total was less than 75% or if number of no plus unclear/total was higher than 25%, significant omissions of the part could be deduced and the validity of the study was questionable. Overall validity (number of yes plus no plus unclear answers should be equal to total) calculation was similar to the part's validity, if number of yes/total was ≥ 75% or if number of no plus unclear/total was ≤ 25%, the validity of study could be confirmed (22) .
In the current study, justification and training about the questions on checklist were carried out in a common meeting before performing CA. The purpose of the meeting was to train and pilot the CA. CA was performed for all 24 studies. In case of any disagreement for the CA scores between the researchers, the issue was rechecked by the third party. The low-quality papers were excluded from the analysis/final report ( Figure 1 ).
Data Extraction
Using a standard checklist, data extraction was carried out by two researchers independently for each included study. Definition of VAP, mortality rate based on the duration of MV, detection rate of bacteria in airway secretions, ICU LOS, the incidence of VAP, the number of patients, year of publication, patients characteristics, and details of the outcomes were collected for each study.
Data Collection Process
The review process was initially commenced by two researchers. Titles and abstracts of the potentially relevant articles were examined according to the described search strategy. Two researchers independently screened the titles and abstracts using a predefined extraction sheet. Full texts of the selected papers were precisely investigated to identify the eligible studies. In case of similar cases, the study with more available relevant data was enrolled. The quality assessment was finally performed for each study by two experts, independently. Then in a meeting, excluded and included studies were discussed. The Kappa statistic (Inter-rater agreement) between the two researchers was 0.93.
Summary Measures
Summary of the prevalence of three outcomes as ICU mortality rate, hospital mortality rate, and VAP incidence in the groups with and without SSD was measured. First, the included studies were sorted according to the publication year and then a cumulative meta-analysis was run.
Synthesis of Results
The random-or-fixed effects model was used in the current study. Heterogeneity between studies was tested by means of Cochran Q (chi-square, N-1 degrees of freedom) and the I 2 statistic using P < 0.05 to indicate heterogeneity. Random-or-fixed effects model was used for the metaanalysis according to the result of heterogeneity tests, by means of the metan command in STATA 11 software (STATA Corp., LP). To determine the statin effects according to the DerSimonian and Laird approach, pooled hazard ratios (HR) and its 95% confidence interval (CI) were also calculated.
Results
Study Selection
In the current umbrella review and meta-analysis, 24 studies with 2434 patients were identified. In addition, 6750 references were identified and 1400 studies were also selected for a secondary review; finally, 24 papers met the inclusion criteria and were enrolled in the meta-analysis.
The inclusion criterion was reporting one of the following items in the study: Duration of expected MV, incidence of VAP, mortality rate, hospital or ICU LOS (Figure 1 ).
Study Characteristics
Clinical and microbiological criteria along with new or persistent pulmonary infiltrates on a chest radiograph were considered for the VAP definition (23) . Table 1 demonstrates the publication year of studies, inclusion criteria, sample size, VAP prevalence, mortality rate, and the ICU LOS of patients in the selected studies. Eighteen studies were included in the analysis of VAP incidence. 
Publication Bias
Meta-analysis of VAP and mortality rate in all included studies showed a significant publication bias (Table 2 and Figure 2 ). The Egger regression asymmetry analysis showed a significant publication bias for VAP (P < 0.0001) and mortality rate (P = 0.003) (Figure 2) . To ensure the accuracy of the results, the sensitivity analysis was used to exclude each study and obtain a pooled estimate of the effects of VAP, mortality rate, and LOS (Figure 3 ). According to Figure 3 , the results of sensitivity analysis showed that none of the studies alone had a significant impact on the pooled effect size estimation of the VAP, mortality rate, and ICU LOS variables.
Results of Individual Studies
The results of two studies reporting the mean mechanical ventilation (MMV) could be aggregated; likewise, MMV duration was 14.9 days (95% CI: 7.3 -22.6) ( Table 2 ) and there was a heterogeneity (P = 0.016, I 2 = 82.9%). The detection rate of bacteria in airway secretions reported only in two RTCs was 10.2% (95% CI: 4.9 -15.5) with no heterogeneity (P = 0.141, I 2 = 53.9%) ( the APACHI score of patients with SSD as 19.5 (95% CI: 14.6 -24.3) with heterogeneity (P < 0.0001, I 2 = 99. 2%) ( Table 2 ).
Synthesis of Results
In the meta-analysis, the primary outcome was the VAP incidence, the overall prevalence of VAP was 14.7 (95% CI: 11.1 -18.4) with heterogeneity (P < 0.0001, I 2 = 87.6%) ( Table   2 and Figure 4 ). Pooled prevalence of mortality rate (ICU or hospital) reported in 13 papers was 25.8 (95% CI: 17.3 -34.3, P < 0.0001) with heterogeneity (P < 0.0001, I 2 = 97.1%) (Table 2 and Figure 5 ). The ICU LOS reported in 13 studies was 13.4 days (95% CI: 7.8 -18.9) with heterogeneity (P < 0.0001, I 2 = 99.6%) ( Table 2 ). In addition, seven studies mentioned the mean of hospital LOS. The overall hospital LOS was 23. Table 2 ).
Discussion
Summary of Evidence
Pooled information from published studies of the effect of SSD on the prevalence of VAP in mechanically ventilated adult patients admitted to ICU was conducted in the current meta-analysis. The study found that SSD significantly reduced the incidence of VAP in all entered studies. Likewise, previous meta-analyses reported that SSD decreased VAP incidence (13) (14) (15) (16) (17) (18) .
In the current study, mortality risk reduction was observed. In contrast, some meta-analyses reported no benefits in terms of reduced ICU or hospital mortality rate (13-16, 18, 48) . Also, the present study showed that SSD could shorten the hospital and/or ICU LOS.
Similar to the current study, some meta-analyses reported that use of SSD decreased ICU LOS (13, 16) . In contrary, some previous meta-analyses showed that in comparison of the SSD and control groups, no reduction in ICU or hospital LOS was observed (14, 15) .
Also, in the current meta-analysis, a slight reduction was observed in days of MV. In fact, the authors found that SSD appears to reduce ventilation duration by about two days in patients who required MV for at least 48 hours. In this regard, several meta-analyses reported that SSD decreased the duration of MV (13) (14) (15) (16) 18) . For instance, the meta-analysis by Dezfulian et al. also showed that the duration of ventilation reduced by about two days when comparing the intervention and control groups (48) . Also, the current meta-analysis confirmed that SSD further reduced the detection rate of bacteria in airway secretions. A recently updated meta-analysis confirmed that SSD reduced the detection rate of bacteria in airway secretions (15) .
Differences between the present and previous metaanalyses are as follows: First, the current meta-analysis included four additional studies (3, (24) (25) (26) published recently, and were not included in previous meta-analyses. As the latest and most comprehensively updated metaanalysis, the present study further reinforced the results of previous meta-analyses. Second, the researchers only considered patients who needed ETT with SSD.
Limitations
Potential limitations of the current meta-analysis were that the eligible RTCs enrolled in the present study included patients with different diagnoses and clinical settings. Also, only RTCs in English and Persian languages were included. Thus, the generalizability of the findings was questionable. Also, any future studies to assess the benefits of SSD in all mechanically ventilated patients may require a sample size of at least 4000 patients in each group (based on the VAP rate in the control group of the study by Kollef et al.) (45 
Conclusions
The current meta-analysis suggested that SSD significantly reduced the prevalence of VAP, mortality rate, the ICU and/or hospital LOS, hospitalization time, duration of MV, and detection rate of bacteria in airway secretions. In summary, SSD is recommended to reduce the risk of VAP and its outcomes. their gratitude to the Clinical Research Development Center of Baqiyatallah Hospital for methodological support. These entities had no role in the collection, analysis, or interpretation of data and writing of the manuscript. of the manuscript. All authors read and approved the final manuscript.
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